Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information.
Hamamoto R, Koyama T, Kouno N, Yasuda T, Yui S, Sudo K, Hirata M, Sunami K, Kubo T, Takasawa K, Takahashi S, Machino H, Kobayashi K, Asada K, Komatsu M, Kaneko S, Yatabe Y, Yamamoto N. Hamamoto R, et al. Among authors: sudo k. Exp Hematol Oncol. 2022 Oct 31;11(1):82. doi: 10.1186/s40164-022-00333-7. Exp Hematol Oncol. 2022. PMID: 36316731 Free PMC article. Review.
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.
Yamamoto N, Shimizu T, Yonemori K, Kitano S, Kondo S, Iwasa S, Koyama T, Sudo K, Sato J, Tamura K, Tomomatsu J, Ono M, Fukuda N, Takahashi S. Yamamoto N, et al. Among authors: sudo k. Invest New Drugs. 2021 Aug;39(4):1036-1046. doi: 10.1007/s10637-020-01055-5. Epub 2021 Feb 9. Invest New Drugs. 2021. PMID: 33560503 Free PMC article. Clinical Trial.
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.
Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Akihiko Y, Yamamoto N, Yonemori K. Takeyasu Y, et al. Among authors: sudo k. JCO Precis Oncol. 2021 May 3;5:PO.20.00383. doi: 10.1200/PO.20.00383. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036223 Free PMC article.
Identification of novel SSX1 fusions in synovial sarcoma.
Yoshida A, Arai Y, Satomi K, Kubo T, Ryo E, Matsushita Y, Hama N, Sudo K, Komiyama M, Yatabe Y, Shibata T, Ichikawa H, Ichimura K, Kawai A, Mori T. Yoshida A, et al. Among authors: sudo k. Mod Pathol. 2022 Feb;35(2):228-239. doi: 10.1038/s41379-021-00910-x. Epub 2021 Sep 9. Mod Pathol. 2022. PMID: 34504309 Free article.
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients.
Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Mizuno T, et al. Among authors: sudo k. Jpn J Clin Oncol. 2021 Dec 1;51(12):1757-1760. doi: 10.1093/jjco/hyab159. Jpn J Clin Oncol. 2021. PMID: 34622931
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers.
Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Okuma HS, et al. Among authors: sudo k. Front Oncol. 2021 Nov 24;11:732525. doi: 10.3389/fonc.2021.732525. eCollection 2021. Front Oncol. 2021. PMID: 34900683 Free PMC article.
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.
Omura T, Takahashi M, Ohno M, Miyakita Y, Yanagisawa S, Tamura Y, Kikuchi M, Kawauchi D, Nakano T, Hosoya T, Igaki H, Satomi K, Yoshida A, Sunami K, Hirata M, Shimoi T, Sudo K, Okuma HS, Yonemori K, Suzuki H, Ichimura K, Narita Y. Omura T, et al. Among authors: sudo k. Cancers (Basel). 2022 May 16;14(10):2454. doi: 10.3390/cancers14102454. Cancers (Basel). 2022. PMID: 35626060 Free PMC article.
Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
Saito A, Tanioka M, Hirata M, Watanabe T, Odaka Y, Shimoi T, Sudo K, Noguchi E, Ishikawa M, Yonemori K. Saito A, et al. Among authors: sudo k. Cancer Treat Res Commun. 2022;32:100587. doi: 10.1016/j.ctarc.2022.100587. Epub 2022 Jun 8. Cancer Treat Res Commun. 2022. PMID: 35696850 Free article.
First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors.
Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. Iwasa S, et al. Among authors: sudo k. Cancer Sci. 2023 Jan;114(1):211-220. doi: 10.1111/cas.15574. Epub 2022 Nov 4. Cancer Sci. 2023. PMID: 36082616 Free PMC article.
896 results